Comparative Pharmacology
Head-to-head clinical analysis: CLOBAZAM versus CLONAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOBAZAM versus CLONAZEPAM.
CLOBAZAM vs CLONAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clobazam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and neuronal hyperpolarization. It has a high affinity for the α2 subunit, which may contribute to its anticonvulsant effects.
Enhances GABA-A receptor inhibitory neurotransmission by binding to benzodiazepine binding site, increasing frequency of chloride channel opening, leading to neuronal hyperpolarization.
10-60 mg orally once daily, divided into two doses. Typical starting dose: 10 mg twice daily.
0.5 mg orally three times daily; maximum 20 mg/day
MODERATE Risk
MODERATE Risk
Clobazam: 36–42 hours; N-desmethylclobazam: 71–82 hours. Steady state achieved in 5–10 days.
Clinical Note
moderateClobazam + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Clobazam."
Clinical Note
moderateClobazam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clobazam is combined with Fluticasone propionate."
Clinical Note
moderateClobazam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clobazam."
Clinical Note
moderateClonazepam + Sulfisoxazole
Terminal elimination half-life: 19-60 hours (mean 30-40 hours); clinical context: long-acting benzodiazepine, allows once or twice daily dosing; accumulation occurs with repeated use.
Renal: ~82% as metabolites (mainly N-desmethylclobazam and hydroxylated metabolites), unchanged clobazam <1%; fecal: ~11%.
Renal: 50-70% as metabolites (mostly glucuronide conjugates), <2% unchanged; fecal: 10-20%; biliary: minor.
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Sulfisoxazole can be decreased when combined with Clonazepam."